Università di Perugia-ko ikertzaileekin lankidetzan egindako argitalpenak (3)

2024

  1. Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial

    Nature Communications, Vol. 15, Núm. 1

2023

  1. Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF -Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial

    Journal of Clinical Oncology, Vol. 41, Núm. 2, pp. 212-221

2010

  1. Seventh annual meeting of the Italian Network for Tumor Biotherapy (NIBIT), Siena, 1-3 October 2009

    Cancer Immunology, Immunotherapy